ИММУНОТЕРАПИЯ МЕЛАНОМЫ
Аннотация
Меланома – это одна из наиболее опасных злокачественных опухолей человека. Агрессивный характер роста с риском формирования отдаленных метастазов является причиной высокого уровня смертности от меланомы кожи во всем мире. Ограниченные возможности таких методов, как хирургия, химиотерапия и лучевая терапия, делают актуальной разработку более эффективных способов лечения. В настоящее время одним из привлекательных подходов для борьбы с опухолевыми клетками является иммунотерапия. В обзоре проанализированы основные направления иммунотерапии меланомы, в том числе подходы в области создания терапевтических вакцин на основе опухолевых клеток, синтетических пептидов и полиэпитопных иммуногенов.
Ключевые слова
меланома,
иммунотерапия,
антигены,
клеточные вакцины,
пептидные вакцины,
ДНК-вакцины,
дендритные клетки
Об авторах
Е. А. Боробова
Сибирский федеральный биомедицинский исследовательский центр им. акад. Е.Н. Мешалкина; ФБУН «Государственный научный центр вирусологии и биотехнологии «Вектор».
Россия
Россия
Боробова Елена Александровна - врач клинической лабораторной диагностики, Сибирский федеральный биомедицинский исследовательский центр им. акад. Е.Н. Мешалкина; младший научный сотрудник, ФБУН ГНЦ ВБ «Вектор».
630055, г. Новосибирск, ул. Речкуновская, 15.
А. А. Жеравин
Сибирский федеральный биомедицинский исследовательский центр им. акад. Е.Н. Мешалкина.
Россия
Россия
Жеравин Александр Александрович, кандидат медицинских наук, руководитель центра онкологии и радиотерапии, Сибирский федеральный биомедицинский исследовательский центр им. акад. Е.Н. Мешалкина.
630055, г. Новосибирск, ул. Речкуновская, 15.
Список литературы
1. Харкевич Г.Ю., Демидов Л.В. Современный взгляд на лекарственное лечение диссеминированной меланомы кожи. Практическая онкология. 2012; 13 (2): 143–149.
2. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S., Eggermont A.M., Flaherty K.T., Gimotty P.A., Kirkwood J.M., McMasters K.M., Mihm M.C.Jr., Morton D.L., Ross M.I., Sober A.J., Sondak V.K. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27 (36): 6199–206. doi: 10.1200/JCO.2009.23.4799
3. Mackensen A., Carcelain G., Viel S., Raynal M.C., Michalaki H., Triebel F., Bosq J., Hercend T. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest. 1994 Apr; 93 (4): 1397–402.
4. Kirkwood J.M., Ernstoff M. Interferons in the treatment of human cancer. J Clin Oncol. 1984; 2 (4): 336–52.
5. Dutcher J.P., Creekmore S., Weiss G.R., Margolin K., Markowitz A.B., Roper M., Parkinson D., Ciobanu N., Fisher R., Boldt D.H. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989; 7 (4): 477–85.
6. Mocellin S., Pasquali S., Rossi C.R., Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010 Apr 7; 102 (7): 493–501. doi: 10.1093/jnci/djq009.
7. Lee S., Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011 Oct 13; 3 (4): 3856–93. doi: 10.3390/cancers3043856.
8. Romano E., Schwartz G.K., Chapman P.B., Wolchock J.D., Carvajal R.D. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol. 2011; 12 (9): 913–22. doi: 10.1016/S1470-2045(10)70274-6.
9. Maldonado J.L., Fridlyand J., Patel H., Jain A.N., Busam K., Kageshita T., Ono T., Albertson D.G., Pinkel D., Bastian B.C. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003; 95 (24): 1878–90.
10. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363 (9): 809–19. doi: 10.1056/NEJMoa1002011.
11. Menzies A.M., Lum T., Wilmott J.S., Hyman J., Kefford R.F., Thompson J.F., O’Toole S., Long G.V., Scolyer R.A. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol. 2014; 38 (3): 377–82. doi: 10.1097/PAS.0000000000000136.
12. Simpson A., Caballero O. Monoclonal antibodies for the therapy of cancer. BMC Proc. 2014; 8 (Suppl 4): O6. doi: 10.1186/1753-6561-8-S4-O6.
13. Wold E.D., Smider V.V., Felding B.H. Antibody therapeutics in oncology. Immunotherapy. Los Angel. 2016; 2 (1).
14. Ben-Kasus T., Schechter B., Lavi S., Yarden Y., Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A. 2009 Mar 3; 106 (9): 3294–9. doi: 10.1073/pnas.0812059106.
15. Scott A.M., Allison J.P., Wolchok J.D. Monoclonal antibodies in cancer therapy. Cancer Immun Arch. 2012; 12 (1): 14.
16. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192 (7): 1027–34.
17. Buchbinder E., Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39 (1): 98. doi: 10.1097/COC.0000000000000239
18. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., Gilson M.M., Wang C., Selby M., Taube J.M., Anders R., Chen L., Korman A.J., Pardoll D.M., Lowy I., Topalian S.L. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1; 28 (19): 3167–75. doi: 10.1200/JCO.2009.26.7609.
19. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., Savage K.J., Hernberg M.M., Lebbé C., Charles J., Mihalcioiu C., Chiarion-Sileni V., Mauch C., Cognetti F., Arance A., Schmidt H., Schadendorf D., Gogas H., Lundgren-Eriksson L., Horak C., Sharkey B., Waxman I.M., Atkinson V., Ascierto P.A. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22; 372 (4): 320–30. doi: 10.1056/NEJMoa1412082.
20. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., Davidson N., Richards J., Maio M., Hauschild A., Miller W.H.Jr., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.T., Humphrey R., Hoos A., Wolchok J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364 (26): 2517–26. doi: 10.1056/NEJMoa1104621.
21. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., Wang L., Kirkesseli S., Rocklin R., Bock B., Hamilton J., Ming J.E., Radin A., Stahl N., Yancopoulos G.D., Graham N., Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013; 368 (26): 2455–66. doi: 10.1056/NEJMoa1304048.
22. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988; 319 (25): 1676–80.
23. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86 (15): 1159–66. doi: 10.1093/jnci/86.15.1159.
24. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., Morton K.E., Laurencot C.M., Steinberg S.M., White D.E., Dudley M.E. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17 (13): 4550–7. doi: 10.1158/1078-0432.CCR-11-0116.
25. Eshhar Z., Waks T., Gross G. The emergence of T-bodies/CAR T cells. Cancer J. 2014; 20 (2): 123–6. doi: 10.1097/PPO.0000000000000027.
26. Robbins P.F., Kassim S.H., Tran T.L., Crystal J.S., Morgan R.A., Feldman S.A., Yang J.C., Dudley M.E., Wunderlich J.R., Sherry R.M., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Li Y.F., El-Gamil M., Rosenberg S.A. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-term followup and correlates with response. Clin Cancer Res. 2015; 21 (5): 1019–27. doi: 10.1158/1078-0432.CCR-14-2708.
27. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., Lee C.C., Restifo N.P., Schwarz S.L., Cogdill A.P., Bishop R.J., Kim H., Brewer C.C., Rudy S.F., VanWaes C., Davis J.L., Mathur A., Ripley R.T., Nathan D.A., Laurencot C.M., Rosenberg S.A. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114 (3): 535–46. doi: 10.1182/blood-2009-03-211714.
28. Ozao-Choy J., Lee D.J., Faries M.B. Melanoma vaccines: mixed past, promising future. Surg Clin North Am. 2014; 94 (5): 1017–30. doi: 10.1016/j.suc.2014.07.005.
29. Hodge J.W., Chakraborty M., Kudo-Saito C., Garnett C.T., Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol. 2005; 174 (10): 5994–6004.
30. Dzutsev A.H., Belyakov I.M., Isakov D.V., Margulies D.H., Berzofsky J.A. Avidity of CD8 T cells sharpens immunodominance. International immunology. 2007; 19 (4): 497–507. doi: 10.1093/intimm/dxm016.
31. Hou Y., Kavanagh B., Fong L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol. 2008; 180 (3): 1526–34.
32. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254 (5038): 1643.
33. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998; 4 (3): 321. doi: 10.1038/nm0398-321.
34. Smith J.W., Walker E.B., Fox B.A., Haley D., Wisner K.P., Doran T., Fisher B., Justice L., Wood W., Vetto J., Maecker H., Dols A., Meijer S., Hu H.M., Romero P., Alvord W.G., Urba W.J. Adjuvant immunization of HLA-A2–positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol. 2003; 21 (8): 1562–73. doi: 10.1200/JCO.2003.09.020.
35. Walker E.B., Haley D., Miller W., Floyd K., Wisner K.P., Sanjuan N., Maecker H., Romero P., Hu H.M., Alvord W.G., Smith J.W., Fox B.A., Urba W.J. gp100209–2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage I‑III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells. Clin Cancer Res. 2004; 10 (2): 668–80. doi: 10.1158/1078-0432.CCR-0095-03.
36. Chianese-Bullock K.A., Pressley J., Garbee C., Hibbitts S., Murphy C., Yamshchikov G., Petroni G.R., Bissonette E.A., Neese P.Y., Grosh W.W., Merrill P., Fink R., Woodson E.M., Wiernasz C.J., Patterson J.W., Slingluff C.L.Jr. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colonystimulating factor and montanide ISA-51 adjuvant and administered as part ofa multipeptide vaccine for melanoma. J Immunol. 2005; 174 (5): 3080–6.
37. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., Gailani F., Riley L., Conlon K., Pockaj B., Kendra K.L., White R.L., Gonzalez R., Kuzel T.M., Curti B., Leming P.D., Whitman E.D., Balkissoon J., Reintgen D.S., Kaufman H., Marincola F.M., Merino M.J., Rosenberg S.A., Choyke P., Vena D., Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364 (22): 2119–27. doi: 10.1056/NEJMoa1012863.
38. Chi M., Dudek A.Z. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. Melanoma Res. 2011; 21 (3): 165–74. doi: 10.1097/CMR.0b013e328346554d.
39. Учайкин В.Ф., Шамшева О.В. Руководство по клинической вакцинологии. М.: 2006, 592.
40. Eggermont A.M., Suciu S., Rutkowski P., Marsden J., Santinami M., Corrie P., Aamdal S., Ascierto P.A., Patel P.M., Kruit W.H., Bastholt L., Borgognoni L., Bernengo M.G., Davidson N., Polders L., Praet M., Spatz A. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor> 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol. 2013 Oct 20; 31 (30): 3831–7. doi: 10.1200/JCO.2012.47.9303.
41. Osorio M., Gracia E., Reigosa E., Hernandez J., de la Torre A., Saurez G., Perez K., Viada C., Cepeda M., Carr A., Avila Y., Rodríguez M., Fernandez L.E. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag Res. 2012; 4: 341–5. doi: 10.2147/CMAR.S22617.
42. Alfonso S., Valdés-Zayas A., Santiesteban E.R., Flores Y.I., Areces F., Hernández M., Viada C.E., Mendoza I.C., Guerra P.P., García E., Ortiz R.A., de la Torre A.V., Cepeda M., Pérez K., Chong E., Hernández A.M., Toledo D., González Z., Mazorra Z., Crombet T., Pérez R., Vázquez A.M., Macías A.E. A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients. Clin Cancer Res. 2014; 20 (14): 3660–71. doi: 10.1158/1078-0432.CCR-13-1674.
43. Harbst K., Lauss M., Cirenajwis H., Winter C., Howlin J., Törngren T., Kvist A., Nodin B., Olsson E., Häkkinen J., Jirström K., Staaf J., Lundgren L., Olsson H., Ingvar C., Gruvberger-Saal S.K., Saal L.H., Jönsson G. Molecular and genetic diversity in the metastatic process of melanoma. J Pathol. 2014; 233 (1): 39–50. doi: 10.1002/path.4318.
44. Senzer N., Barve M., Kuhn J., Melnyk A., Beitsch P., Lazar M., Lifshitz S., Magee M., Oh J., Mill S.W., Bedell C., Higgs C., Kumar P., Yu Y., Norvell F., Phalon C., Taquet N., Rao D.D., Wang Z., Jay C.M., Pappen B.O., Wallraven G., Brunicardi F.C., Shanahan D.M., Maples P.B., Nemunaitis J. Phase I trial of “bi-shRNAi furin/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol Ther. 2012; 20 (3): 679–86. doi: 10.1038/mt.2011.269.
45. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines. 2004; 3 (5): 521–7. doi: 10.1586/14760584.3.5.521.
46. Guo C., Manjili M.H., Subjeck J.R., Sarkar D., Fisher P.B., Wang X-Y. Therapeutic cancer vaccines: past, present and future. Adv Cancer Res. 2013; 119: 421–75. doi: 10.1016/B978-0-12-407190-2.00007-1.
47. Lipson E.J., Sharfman W.H., Chen S., McMiller T.L., Pritchard T.S., Salas J.T., Sartorius-Mergenthaler S., Freed I., Ravi S., Wang H., Luber B., Sproul J.D., Taube J.M., Pardoll D.M., Topalian S.L. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med. 2015 Jul 5; 13: 214. doi: 10.1186/s12967-015-0572-3.
48. Chlichlia K., Schirrmacher V., Sandaltzopoulos R. Cancer immunotherapy: Battling tumors with gene vaccines. Curr Med Chem Anti Inflamm Anti Allergy Agents. 2005; 4 (4): 353–65. doi: 10.2174/1568014054546290.
49. Herrada A.A., Rojas-Colonelli N., González-Figueroa P., Roco J., Oyarce C., Ligtenberg M.A., Lladser A. Harnessing DNA-induced immune responses for improving cancer vaccines. Hum Vaccin Immunother. 2012; 8 (11): 1682–93.doi: 10.4161/hv.22345.
50. Coulie P.G., Van den Eynde B.J., Van Der Bruggen P., Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014; 14 (2): 135–46. doi: 10.1038/nrc3670.
51. Bloy N., Buqué A., Aranda F., Castoldi F., Eggermont A., Cremer I., Sautes-Fridman C., Fucikova J., Galon J., Spisek R. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015; 4 (5): e1026531. doi: 10.1080/2162402X.2015.1026531.
52. Liu B.-B., Wang W.-H. Survivin and pancreatic cancer. World J Clin Oncol. 2011 Mar 10; 2 (3): 164–8. doi: 10.5306/wjco.v2.i3.164.
53. Grosenbaugh D.A., Leard A.T., Bergman P.J., Klein M.K., Meleo K., Susaneck S., Hess P.R., Jankowski M.K., Jones P.D., Leibman N.F., Johnson M.H., Kurzman I.D., Wolchok J.D. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res. 2011 Dec; 72 (12): 1631–8. doi: 10.2460/ajvr.72.12.1631.
54. Yuan J., Ku G.Y., Gallardo H.F., Orlandi F., Manukian G., Rasalan T.S., Xu Y., Li H., Vyas S., Mu Z. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun Arch. 2009; 9 (1): 5.
55. Wolchok J.D., Yuan J., Houghton A.N., Gallardo H.F., Rasalan T.S., Wang J., Zhang Y., Ranganathan R., Chapman P.B., Krown S.E., Livingston P.O., Heywood M., Riviere I., Panageas K.S., Terzulli S.L., Perales M.A. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther. 2007; 15 (11): 2044–50. doi: 10.1038/sj.mt.6300290.
56. Dangoor A., Lorigan P., Keilholz U., Schadendorf D., Harris A., Ottensmeier C., Smyth J., Hoffmann K., Anderson R., Cripps M., Schneider J., Hawkins R. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother. 2010; 59 (6): 863–73. doi: 10.1007/s00262-009-0811-7.
57. Tiptiri-Kourpeti A., Spyridopoulou K., Pappa A., Chlichlia K. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Pharmacol Ther. 2016; 165: 32–49. doi: 10.1016/j.pharmthera.2016.05.004.
58. Draube A., Klein-González N., Mattheus S., Brillant C., Hellmich M., Engert A., von Bergwelt-Baildon M. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PloS one. 2011; 6 (4): e18801. doi: 10.1371/journal.pone.0018801.
59. Strobl H., Bello-Fernandez C., Riedl E., Pickl W.F., Majdic O., Lyman S.D., Knapp W. flt3 ligand in cooperation with transforming growth factor-β1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serumfree conditions. Blood. 1997; 90 (4): 1425–34.
60. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 2001; 61 (17): 6451–8.
61. Batich K.A., Swartz A.M., Sampson J.H. Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. Methods Mol Biol. 2016; 1403: 819–38. doi: 10.1007/978-1-4939-3387-7_47.
62. Anguille S., Smits E.L., Lion E., van Tendeloo V.F., Berneman Z.N. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014; 15 (7): e257‑e67. doi: 10.1016/S1470-2045(13)70585-0.
63. Anguille S., Smits E.L., Bryant C., Van Acker H.H., Goossens H., Lion E., Fromm P.D., Hart D.N., Van Tendeloo V.F., Berneman Z.N. Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacol Rev. 2015; 67 (4): 731–53. doi: 10.1124/pr.114.009456.
64. Григорьев Е.В., Шукевич Д.Л., Матвеева В.Г., Пугачев С.В., Каменева Е.А., Корнелюк Р.А. Миелоидные супрессорные клетки в патогенезе критических состояний. Патология кровообращения и кардиохирургия. 2016; 20 (3): 20–25. doi:10.21688-1681-3472-2016-3-20-25.
65. Cheever M.A., Higano C.S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011; 17 (11): 3520–6. doi: 10.1158/1078-0432.CCR-10-3126.
66. Bol K.F., Aarntzen E.H., Hout F.E., Schreibelt G., Creemers J.H., Lesterhuis W.J., Gerritsen W.R., Grunhagen D.J., Verhoef C., Punt C.J., Bonenkamp J.J., de Wilt J.H., Figdor C.G., de Vries I.J. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology. 2016; 5 (1): e1057673. doi:10.1080/2162402X.2015.1057673.
67. von Euw E.M., Barrio M.M., Furman D., Levy E.M., Bianchini M., Peguillet I., Lantz O., Vellice A., Kohan A., Chacón M. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. J Transl Med. 2008; 6 (1): 6. doi: 10.1186/1479-5876-6-6.
68. Bol K.F., Mensink H.W., Aarntzen E.H., Schreibelt G., Keunen J.E., Coulie P.G., De Klein A., Punt C.J., Paridaens D., Figdor C.G. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. Am J Ophthalmol. 2014; 158 (5): 939–47. doi: 10.1016/j.ajo.2014.07.014.
69. Tel J., Aarntzen E.H., Baba T., Schreibelt G., Schulte B.M., Benitez-Ribas D., Boerman O.C., Croockewit S., Oyen W.J., van Rossum M. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer res. 2013; 73 (3): 1063–75. doi: 10.1158/0008-5472.CAN-12-2583.
70. Lion E., Smits E.L., Berneman Z.N., Van Tendeloo V.F. NK cells: key to success of DC-based cancer vaccines? Oncologist. 2012; 17 (10): 1256–70. doi: 10.1634/theoncologist.2011-0122.
71. Boudewijns S., Bol K.F., Schreibelt G., Westdorp H., Textor J.C., van Rossum M.M., Scharenborg N.M., de Boer A.J., van de Rakt M.W., Pots J.M. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology. 2016; 5 (7): e1191732. doi: 10.1080/2162402X.2016.1191732.
72. Boudewijns S., Bloemendal M., Gerritsen W.R., de Vries I.J.M., Schreibelt G. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. Hum Vaccin Immunother. 2016; 12 (10): 2523–8. doi: 10.1080/21645515.2016.1197453.
73. Coban C., Kobiyama K., Aoshi T., Takeshita F., Horii T., Akira S., J. Ishii K. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther. 2011; 11 (6): 479–84. doi: 10.2174/156652311798192815
Для цитирования:
Боробова Е.А., Жеравин А.А. ИММУНОТЕРАПИЯ МЕЛАНОМЫ. Сибирский онкологический журнал. 2017;16(4):65-75. https://doi.org/10.21294/1814-4861-2017-16-4-65-75
For citation:
Borobova E.A., Zheravin A.A. IMMUNOTHERAPY FOR MELANOMA. Siberian journal of oncology. 2017;16(4):65-75. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-4-65-75
Просмотров: 571
Послать статью по эл. почте 
